samedan logo
 
 
 
spacer
home > ebr > winter 2017 > super screening
PUBLICATIONS
European Biopharmaceutical Review

Super Screening

To fully understand the details of a biological mechanism at the molecular level, it is important to characterise the biomolecular interaction in a relevant environment without modifying the samples or applying purification procedures.

Enabling this is the advent of a robust and easy-to-use fluidic system, and the injection of complex samples without dilution – such as serum, plasma, cell supernatants or even lysates – is no longer an issue for diagnostic research or drug screening. Moreover, crude samples can also be immobilised on the sensor chip for a rapid and high-throughput quantification that can be utilised in pharmaceutical R&D. The immobilised biological molecules may be quantified in different crude supernatants with only a single injection of the target.

The following discussion examines a biomarker – which we will call ‘Protein Y’ (PY) – which is a component of the HIV structure. This protein is commonly employed as an AIDS diagnosis tool in combination with other immunological tests. Until recently, enzyme-linked immunosorbent assay (ELISA) has been the standard method for PYbased diagnoses. Nevertheless, this method shows some limitations in terms of rapidity and high-throughput, which are increasingly required in pharma R&D. Now, however, there is a good alternative to the use of ELISA in determining the protein concentration. Unlike ELISA – which needs labelling and is time-consuming – surface plasmon resonance imaging (SPRi) is label-free and takes only a few minutes to screen a huge panel of samples.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Fatima-Ezzahra Hibti joined Genoptic – which later became HORIBA Scientific – as Application Engineer in 2009 after graduating from the Université de Reims Champagne- Ardenne, France, with a Master’s degree in Biotechnology and Therapeutic Strategies. For more than seven years, she was involved in various national and European projects and is now in charge of customer feasibility experiments. Fatima-Ezzahra is currently working with the life sciences team to develop the SPRi platform, as well as new applications for it in collaboration with the SPRi team and external partners.

Dr Chiraz Frydman is the Product Manager of Life Science Instruments at HORIBA Scientific. In 1996, she received her engineering diploma in Biology and an MSc in Applied Chemistry and Industrial Process Engineering the following year. After completing her PhD in Enzymatic Engineering, Bioconversion and Microbiology, Chiraz set up her own company dedicated to developing immune-affinity kits. Following this, she worked as a Biophotonic Project Manager at Opticsvalley.

spacer
Fatima-Ezzahra Hibti
spacer
spacer
spacer
Dr Chiraz Frydman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical trials in the post Brexit Europe

While negotiations are still ongoing, the structure of the post-Brexit medicine testing and approval process is still unclear, and the UK government has so far ruled out an extension to the transition period which is due to come to an end at the end of this year.
More info >>

White Papers

Inhaler Adherence: Exploring Key Factors

Aptar Pharma

Aptar Pharma recently hosted an expert panel roundtable on “Inhaler Adherence”. This international scientific forum was held in Paris, France on November 29th 2013. The roundtable was organized to explore and exchange views on the issues which may influence inhaler adherence/ compliance with a particular focus on asthma and C.O.P.D. therapies and their corresponding inhaler devices (MDIs, DPIs).
More info >>

 
Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement